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Methamphetamine (meth) is a potent psychostimulant known to cause neurotoxicity. Clinical reports suggest meth abuse is a risk factor for Parkinson's disease. We investigated changes in the blood-brain barrier and cerebral vasculature as a mechanism underlying this risk in rats treated acutely and trained to self-administer meth. We observed blood-brain barrier leakage in rats treated acutely with meth. Hypoperfusion in the striatum was detected with acute and chronic meth treatment and was associated with hypoxia. This was correlated with reductions in striatal tyrosine hydroxylase in rats trained to self-administer meth. These findings suggest a new mechanism of meth-induced neurotoxicity involving striatal vasoconstriction resulting in hypoxia and dopamine reductions leading to an increased risk for Parkinson's disease for meth abusers. Introduction Methamphetamine (meth) and its active metabolite amphetamine, are indirect agonists causing excessive release of dopamine (DA) and other neurotransmitters in the striatum and other brain regions [1] . With an estimated 26 million abusers globally (US DEA 2006 International Drug Enforcement Conference), the use of this potent psychostimulant has been made more alarming by recent studies indicating an increased risk of developing Parkinson's disease in patients with a history of meth abuse [2] . The nigrostriatal DA pathway is particularly vulnerable to the neurotoxic effects of meth [3] . Postmortem studies revealed that chronic meth abusers of unknown abuse intensity displayed reduced striatal DA function [4] . Chronic meth abusers detoxified for at least 11 months also displayed motor deficits [5] similar to that observed in patients with Parkinson's disease. High-dose meth treatment has also been shown to produce Parkinson's disease-like lesions in numerous animal models [6] . Therefore, preclinical studies complement the aforementioned clinical reports and show reductions in DA function in the striatum of rats following chronic meth administration [3, 7] , similar to the neuropathology displayed in early Parkinson's disease [8] . Unfortunately, the mechanism(s) underlying this increased risk are unknown. It has been hypothesized that meth-induced DA efflux promotes the production of DA quinones and/or reactive oxygen species that facilitate the neurotoxicity and neuroinflammation riddle [9] [10] [11] . Additionally, meth neurotoxicity may stem from bloodbrain barrier dysfunction or hyperthermia [1, 12] .
The present study indicates a novel mechanism for methinduced DA neuron loss and is the first to propose methinduced hypoxia in the striatum as a potential mechanism of neurotoxicity.
Materials and methods

Animals
Male Sprague-Dawley rats (n = 43; Harlan Laboratories, Indianapolis, Indiana, USA) weighing 225-250 g upon arrival were housed in pairs, handled daily, and acclimated to environmentally controlled conditions for 1 week before experimentation. They had access to food and water ad libitum throughout the study. All procedures were performed in accordance with the Guide for the Care and Use of Laboratory Animals (National Research Council, Washington DC) with protocols approved by the Rush University Institutional Animal Care and Use Committee.
Acute meth administration (+) Meth HCl (Sigma, St Louis, Missouri, USA) was dissolved in saline and all doses reflect the base. Rats were administered an intraperitoneal injection of 3 or 9 mg/kg meth (n = 12 per treatment group), or 0.9% saline (n = 10). Doses were selected based on prior studies indicating that 2.5 mg/kg meth-induced brain and behavioral activity without overt signs of toxicity [13] whereas 9 mg/kg altered brain and behavioral function and induced neurotoxicity [14] . Two or 24 h after meth treatment, rats were anesthetized and perfused with fluorescein isothiocyanate-labeled albumin (FITC-LA) to assess acute effects of meth on the blood-brain barrier integrity and vascularity.
Chronic meth self-administration
Rats were instrumented with jugular vein catheters as previously described [15] and trained to self-administer meth for 27 days with assessments testing meth-seeking behavior every 2 days between days 15 and 27 (n = 5). Rats self-administered meth on a fixed ratio 1 schedule of reinforcement on days 1-7 and fixed ratio 5 schedule on all subsequent self-administration sessions lasting 3 h/day. Meth was administered at 0.1 mg/kg/0.1 ml infusion. On an average, the rats self-administered 2-3 mg/kg meth over 3 h. Between days 28 and 37, rats were withdrawn from meth and remained in their home cages. The rats were administered an acute 1 mg/kg noncontingent injection of meth on days 34 and 35 for motor assessments, and were given no further meth after day 35 before perfusion.
Fluorescein isothiocyanate labeled albumin intracardial perfusions
At the designated kill times, rats were anesthetized with 400 mg/ml/kg chloral hydrate and perfused with FITC-LA (MW = 68-70 kDa; Sigma) to assess vascular leakage and perfusion [16] .
Immunohistochemistry
Forty micrometer sections were labeled overnight with antibodies for the marker for DAergic neurons {Tyrosine hydroxylase-immunoreactive [TH-ir; mouse vs. rat TH (1 : 10 000); Immunostar, Hudson, Wisconsin, USA]}, and for the marker of hypoxic injury {hypoxia inducible factor 1a [HIF1a; rabbit vs. rat HIF1a (1 : 100); Millipore, Temecula, California, USA]} followed by incubation with species appropriate secondary antibodies (1 : 200; Vector Labs, Burlingame, California, USA). TH-ir and HIF1a were visualized using a peroxidase-conjugated avidinbiotin complex and 3,3-diaminobenzidine.
Optical density measurements
Optical density was assessed using ImageJ (NIH, Bethesda, Maryland, USA). Photomicrographs of FITC-LA taken at 10 Â magnification of the prefrontal cortex, striatum, and nucleus accumbens shell were selected based on anatomical landmarks. A 200 mm 2 box was traced around each region to measure optical density. Selected optical densities were measured in the prefrontal cortex and nucleus accumbens shell. An observer blinded to the treatment identified two photomicrographs from these regions that seemed to have the most leakage for each rat treated with 3 or 9 mg/kg meth. Optical densities were measured for the selected sections as well as for the serial sections that were immediately rostral and caudal and then averaged. Optical density averages were compared with yoked sections from rats treated with saline or trained to self-administer meth. For TH-ir, striatal optical density was measured in photomicrographs taken at 2.5 Â magnification. A 16 mm 2 field from the center of the striatum was measured. In addition, optical density of two 1 mm 2 fields, from the anterior commissure and lateral septum in the same section were used to determine background staining to normalize for procedural variability. The averaged background was then subtracted from the averaged value of the striatal field [17].
Stereological assessments
An Olympus BX60 microscope (Olympus, Center Valley, Pennsylvania, USA) with a computer-controlled motorized stage, high sensitivity HV-C20 CCD video camera (Hitachi Kokusai Electric Canada Ltd, Scarborough, Ontario, Canada) and StereoInvestigator software version 5.1 (MicroBrightField, Colchester, Vermont, USA) was used to estimate TH-ir cell counts and volume within the substantia nigra pars compacta in equidistant serial sections. The number of TH-ir-positive cells was counted within the thickness of the tissue section under an Olympus 100 Â objective (Olympus) using the unbiased three-dimensional counting. Six sections containing the substantia nigra were quantified per animal and approximately 20% of the region was quantified using a 200 Â 200 mm counting frame. The total number of THir-positive cells and the volume of tissue evaluated were divided to obtain a density measurement expressed as total number/mm 3 .
Statistics
Optical density data is presented as mean ± SEM. A oneway analysis of variance was used to analyze the differences in optical density measurements in the prefrontal cortex, striatum, and nucleus accumbens shell of rats treated with saline, 3 mg/kg meth, 9 mg/kg meth, and rats trained to self-administer meth. When appropriate, a Newman-Keuls post-hoc analysis was used. For all analyses, a = 0.05. Data were analyzed using SPSS Statistics (IBM, Somers, New York, USA).
Results
FITC-LA imaging (Fig. 1a ) and fluorescence intensity measurements ( Fig. 2a ) indicated that FITC-LA leakage did not occur throughout all brain regions, but appeared as punctate areas of FITC-LA leakage in the prefrontal cortex and nucleus accumbens shell of rats acutely treated with meth and perfused at 2 and 24 h postmeth; no leakage was observed in rats trained to self-administer meth (Fig. 1a ). FITC-LA leakage was also observed within the circumventricular areas of the hypothalamus where the blood-brain barrier is absent (data not shown; [18] ).
Although FITC-LA produced a normal vascular pattern in the dorsal striatum and all neighboring areas (e.g. parietal cortex) in the saline-treated rats, FITC-LA was overtly reduced in the dorsal striatum in rats acutely treated with meth and perfused at both 2 and 24 h posttreatment as well as in rats trained to self-administer meth (Fig. 1b) . The absence of FITC-LA filled large vessels in the dorsal striatum was distinct from that observed in adjacent structures including the parietal cortex and nucleus accumbens where FITC-LA appeared to fill the vasculature normally. Quantification of fluorescence intensity in the dorsal striatum revealed a significant decrease in FITC-LA within the dorsal striatum of meth-treated animals compared with saline controls ( Fig. 2a ; F (3,106) = 221.119; P < 0.05).
The reduction in FITC-LA in the dorsal striatum observed in rats 10 days after the meth self-administration suggested that meth-induced hypoperfusion was long-lived and may lead to ischemic hypoxia. Consequently, hypoxia was assessed using HIF1a, an oxygendependent transcription factor that is upregulated as early as 4 h after hypoxic injury [19] . An apparent increase in HIF1a immunostaining was observed in the dorsal striatum of rats treated acutely with meth and perfused at 24 h, but not 2 h, after meth injection as well as in rats that self-administered meth (Fig. 1c ). HIF1a immunostaining appeared normal in neighboring brain regions 
Meth selfadministration
Effects of meth on fluorescein isothiocyanate-labeled albumin (FITC-LA), hypoxia inducible factor 1 a, and tyrosine hydroxylase-immunoreactive (THir) immunostaining in the nucleus accumbens shell and striatum of rats. (a) Blood-brain barrier disruption 24 h following acute 3 and 9 mg/kg meth shown by FITC-LA in the nucleus accumbens shell. Ten days following meth self-administration, no leakage was observed (scale bar 250 mm). (b) Hypoperfusion in the dorsal striatum shown by FITC-LA in rats treated with acute 3 or 9 mg/kg meth and 10 days after self-administration (scale bar 250 mm). (c) Hypoxia inducible factor 1 a immunostaining in the dorsal striatum shows increased staining in rats treated with acute 3 and 9 mg/kg meth and 10 days after self-administration when compared with saline controls (scale bar 250 mm). (d) TH-ir immunostaining in the striatum shows reductions in TH-ir immunostaining only in rats sacrificed 10 days after meth self-administration (scale bar 500 mm). All photomicrographs were taken at the level where the corpus callosum hits the midline. Nucleus accumbens shell (NAc-s); Striatum (Str); dorsal striatum (dStr).
including the cortex and was similar to the low level of staining observed in saline controls.
Quantification of the density of TH-ir, a standard marker for DA neurons and their process terminals, revealed a significant decrease in striatal TH-ir in rats trained to self-administer meth ( Fig. 2b; F (3, 32) = 14.777; P < 0.05). Stereological assessment of TH-ir-positive cell bodies in the substantia nigra pars compacta, the source of striatal DA terminals, resulted in an 18% decrease in cell counts in rats withdrawn from meth self-administration compared with controls ( Fig. 2c; F (3, 30) = 10.964). No differences in TH-ir cell counts were observed in rats acutely administered meth compared with saline controls.
Discussion
The present study revealed effects of meth on the bloodbrain barrier, cerebral vasculature, hypoxia, and the DA system. FITC-LA leakage, a measure of blood-brain barrier dysfunction, was observed in the prefrontal cortex and nucleus accumbens shell of rats treated acutely with 3 and 9 mg/kg meth and perfused at 2 and 24 h postmeth similar to the findings of Kiyatkin et al. [12] . Rats trained to self-administer meth and sacrificed 10 days later did not exhibit blood-brain barrier leakage. The varying effects of acute and chronic meth treatment may be a consequence of the higher acute doses compared with the 2-3 mg/kg of meth self-administered over 3 h or withdrawal from self-administration for 10 days and subsequent repair of the damaged blood-brain barrier.
While assessing blood-brain barrier dysfunction using FITC-LA, we were surprised to discover a significant reduction in perfusion of the dorsal striatum following both acute and chronic meth administration. We repeated the acute treatment studies multiple times while monitoring cardiac perfusion pressure to ensure that it was similar to systemic blood pressure (monitored in the tail) and consistently observed the same hypoperfusion suggesting that the outcome was not technique-based. We then observed the same results in rats trained to selfadminister meth and perfused 10 days after the last selfadministration session, suggesting that the hypoperfusion was long-lived. Although the cortex and dorsal striatum are both supplied by the middle cerebral artery, only the striatal region exhibited severe vasoconstriction with meth administration resulting in an upregulation of HIF1a in the striatum and not the cortex. This suggests that meth may interact with brain parenchyma to alter regional vascularity in the striatum through the neurovascular unit [20] . Therefore, the striatal neurovascular unit may release vasoactive factors not produced in other brain regions resulting in local vasoconstriction due to meth exposure.
A possible mechanistic link between meth-induced hypoxia and loss of DA terminals in the striatum involves the upregulation of HIF1a observed in all meth-treated rats. HIF1a is upregulated in the striatum at 24 h following acute meth treatment and may potentiate persistent hypoperfusion in the striatum through its interactions with hypoxia response elements of genes for vasoregulatory factors, including endothelin-1, a potent vasoconstrictor [21] . Increased endothelin-1 release from the cerebral vasculature into the striatum may result in further vasoconstriction and persistent hypoperfusion, as observed in rats sacrificed 10 days following the discontinuation of meth self-administration. Interestingly, studies show that increased endothelin-1 activity at striatal endothelin-1 type B receptors located on DA terminals during hypoxia results in impaired DA release and potential DA terminal toxicity [22, 23] . Furthermore, endothelin-1 is regulated by DA [23] and excess DA released by the action of meth within the striatum may increase striatal endothelin-1 levels leading to a shift in the vasoregulatory balance towards vasoconstriction and increased endothelin-1 activity at striatal endothelin-1 type B receptors on DA terminals that can lead to DA terminal damage.
The persistent hypoperfusion profile seen in the striatum of rats trained to self-administer meth concurs with clinical reports that meth abusers free from drugs for 8-24 months similarly show decreased regional cerebral blood flow in the putamen, cerebral cortex, and right anterior cingulated cortex [24, 25] . Although Chung et al. [25] observed a similar effect in the striatum of patients, we did not observe reduced perfusion in the cortex or cingulated cortex. This may reflect differences in perfusion across species, differences between assessing cerebral blood flow formally, and our simple assessment of perfusion only, or species differences in the effects of meth in the cortex.
It is possible then that the persistent hypoperfusion leads to hypoxia, which is supported by our findings that increased HIF1a immunostaining was observed only in the dorsal striatum of meth-treated rats and not in saline controls or in the neighboring regions of the meth-treated rats displaying normal vasculature with FITC-LA. Methinduced hypoxia in the dorsal striatum would render this structure vulnerable to further neuronal damage. Accordingly, we observed significant reductions in striatal TH-ir terminal density in rats with a history of meth selfadministration. Therefore, meth exposure resulting in reductions of TH-ir is an indication of potential DA terminals and neuron damage within the nigrostriatal pathway, and could, therefore, increase the risk for Parkinson's disease development.
Conclusion
We provide evidence that meth exposure leads to striatal hypoperfusion and increased production of HIF1a, that the hypoperfusion and hypoxia produced by chronic selfadministration lasts at least 10 days, and that these changes are associated with reductions in TH-ir-positive terminals in the striatum. These data provide new insights into meth-induced neurotoxicity and provide a potential mechanism underlying meth abuse as a risk factor for Parkinson's disease development later in life.
